



**State of Louisiana**  
Louisiana Department of Health  
Bureau of Health Services Financing

**MEMORANDUM**

**DATE:** October 27, 2023

**TO:** All Louisiana Medicaid Prescribing Providers and Pharmacists

**FROM:** Kimberly Sullivan, Interim Medicaid Executive Director *KLS*

**SUBJECT:** Louisiana Medicaid Pharmacy Point of Sale (POS) Therapeutic Duplication- October 2023

Effective October 28, 2023, the Louisiana Medicaid Fee for Service (FFS) Pharmacy Program and Managed Care Organizations (MCOs), in consultation with the Drug Utilization Review (DUR) Board, will implement new Point of Sale (POS) therapeutic duplication edits on select drugs. The therapeutic duplication edits apply to pharmacy claims submitted to FFS and MCOs (Aetna, AmeriHealth Caritas, Healthy Blue, Humana Healthy Horizons, Louisiana Healthcare Connections, and UnitedHealthcare). On October 28, 2023, Magellan Medicaid Administration (MMA) will serve as the Pharmacy Benefits Manager (PBM) for MCO pharmacy claims.

**Point of Sale Therapeutic Duplication of Abilify Asimtufii® with Another Injectable Antipsychotic Agent**

An incoming pharmacy claim for aripiprazole (Abilify Asimtufii®) will deny if there is an active prescription on file for another injectable antipsychotic agent. Conversely, an incoming claim for an injectable antipsychotic agent will deny if there is an active prescription on file for aripiprazole (Abilify Asimtufii®).

**Point of Sale Therapeutic Duplication of Risperidone (Uzedy®) with Another Injectable Antipsychotic Agent**

An incoming pharmacy claim for risperidone (Uzedy™) will deny if there is an active prescription on file for another injectable antipsychotic agent. Conversely, an incoming claim for an injectable antipsychotic agent will deny if there is an active prescription on file for risperidone (Uzedy™).

Pharmacy claims for agents which have a therapeutic duplication with another agent will deny with the following:

MCO Only: The pharmacy claim will deny with a **NCPDP rejection code**.

FFS Only: **NCPDP rejection code 88** (DUR reject error) mapped to **EOB code 482** (Therapeutic Duplication).

Override provisions are available. After consultation with the prescriber to verify the medical necessity of the override, the pharmacist may override the denial by submitting the following override codes at POS:

**439-E4 Field** (Reason for Service Code) – **TD** (Therapeutic Duplication)

**440-E5 Field** (Professional Service Code) – **MØ** (Prescriber Consulted)

**441-E6 Field** (Result of Service Code) – **1G** (Filled with Prescriber Approval)

**Additional Information:**

MCO Only: If an override is required, or additional assistance needed, contact Magellan's pharmacy help desk. (See contact information at the end of this document.)

Refer to <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf> for the PDL, which is inclusive of the *Louisiana Uniform Prescription Drug Prior Authorization Form*, medication list, and clinical criteria.

If you have questions about the content of this memo, you may contact the FFS pharmacy help desk by phone at (800) 437-9101.

If you have questions about pharmacy claims billing, you may contact the appropriate plan at their pharmacy help desk listed in the chart below.

Healthcare Provider	Pharmacy Help Desk	Pharmacy Help Desk Phone Number
Aetna, AmeriHealth Caritas, Healthy Blue, Humana Healthy Horizons, Louisiana Healthcare Connections, UnitedHealthcare	Magellan*	(800) 424-1664
Fee for Service	Gainwell Technologies	(800) 648-0790

\*On October 23, 2023, the Magellan pharmacy help desk will be the appropriate contact for the MCO plans.

Please forward this notice to other providers to assist with notification. Your continued cooperation and support of the Louisiana Medicaid Program efforts to coordinate care and improve health are greatly appreciated.

KS/MBW/GJS

c:     Healthy Louisiana Plans  
          Melwyn B. Wendt  
          Gainwell Technologies  
          Magellan